$208.7 Million

Entrada Therapeutics, Inc.

Initial Public Offering

Bookrunner, October 2021

Entrada Therapeutics, Inc. (the “Company”) is a biotechnology company focused on establishing its proprietary endosomal escape vehicles (“EEVs”) as a new class of medicines.  The Company’s EEV therapeutics are designed to engage intracellular targets that have long been considered inaccessible and undruggable. Through its proprietary, highly versatile and modular EEV platform, the Company is building a robust pipeline of EEV therapeutic candidates designed to enable the efficient intracellular delivery of therapeutics in various organs and tissues with an increased therapeutic index.  The Company is initially focused on the development of EEV therapeutics for rare neuromuscular diseases, including Duchenne muscular dystrophy (“DMD”) and myotonic dystrophy type 1 (“DM1”).